Evidence map›Paper›PMID 36610427›Full record

ArticleThe journal of applied laboratory medicine2023

Technology Platforms and Approaches for Building and Evaluating Machine Learning Methods in Healthcare.

Sean D Mooney

Open access · greenAbstract read
In one paragraph

Article in The journal of applied laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Sean D MooneyInstitute for Medical Data Science and Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.ORCID 0000-0003-2654-0833
University of Washington · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Central Hub for Kidney Precision MedicineU24DK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$21.1M
ConProject-002U2CDK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI KRETZLER, MATTHIAS · 2017 to 2021
$21.0M
Variation, Function, and Disease Supplement ProgramU01HG008657 · NHGRI · UNIVERSITY OF WASHINGTON · PI David Russell Crosslin, Gail Pairitz Jarvik · 2015 to 2026
$13.4M
UW Core Center for Clinical Research of Musculoskeletal ConditionsP30AR072572 · NIAMS · UNIVERSITY OF WASHINGTON · PI JEFFREY G JARVIK, Pradeep Suri · 2017 to 2026
$8.3M
Supporting IGVF by modeling genetics, function, and phenotype with machine learningU01HG012022 · NHGRI · NORTHEASTERN UNIVERSITY · PI Predrag Radivojac · 2021 to 2026
$3.4M
University of Illinois at Chicago KPMP CKD Recruitment SiteU01DK133081 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JAMES P. LASH, Ana Catherine Ricardo · 2022 to 2026
$2.7M
NCATS NIH HHS UL1 TR002319NHGRI NIH HHS U01 HG008657NHGRI NIH HHS U01 HG012022NIAMS NIH HHS P30 AR072572NIA NIH HHS U24 AG072122NIDDK NIH HHS U01 DK133081NIDDK NIH HHS U24 DK114886NIDDK NIH HHS U2C DK114886
6 · The paper itself

Abstract

backgroundArtificial intelligence (AI) methods are becoming increasingly commonly implemented in healthcare as decision support, business intelligence tools, or, in some cases, Food and Drug Administration-approved clinical decision-makers. Advanced lab-based diagnostic tools are increasingly becoming AI driven. The path from data to machine learning methods is an active area for research and quality improvement, and there are few established best practices. With data being generated at an unprecedented rate, there is a need for processes that enable data science investigation that protect patient privacy and minimize other business risks. New approaches for data sharing are being utilized that lower these risks. CONTENT: In this short review, clinical and translational AI governance is introduced along with approaches for securely building, sharing, and validating accurate and fair models. This is a constantly evolving field, and there is much interest in collecting data using standards, sharing data, building new models, evaluating models, sharing models, and, of course, implementing models into practice. SUMMARY: AI is an active area of research and development broadly for healthcare and laboratory testing. Robust data governance and machine learning methodological governance are required. New approaches for data sharing are enabling the development of models and their evaluation. Evaluation of methods is difficult, particularly when the evaluation is performed by the team developing the method, and should ideally be prospective. New technologies have enabled standardization of platforms for moving analytics and data science methods.

Indexed as

Artificial IntelligenceMachine LearningDelivery of Health CareHumansProspective StudiesTechnologyUnited States

Identifiers

PMID36610427
PMCPMC10729736
OpenAlexW4313703109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.